Sulfapyridin
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1. -
Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks
processes Review Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks Manuel Conde-Cid 1, Avelino Núñez-Delgado 2 , María José Fernández-Sanjurjo 2 , Esperanza Álvarez-Rodríguez 2, David Fernández-Calviño 1,* and Manuel Arias-Estévez 1 1 Soil Science and Agricultural Chemistry, Faculty Sciences, University Vigo, 32004 Ourense, Spain; [email protected] (M.C.-C.); [email protected] (M.A.-E.) 2 Department Soil Science and Agricultural Chemistry, Engineering Polytechnic School, University Santiago de Compostela, 27002 Lugo, Spain; [email protected] (A.N.-D.); [email protected] (M.J.F.-S.); [email protected] (E.Á.-R.) * Correspondence: [email protected] Received: 30 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Veterinary antibiotics are widely used worldwide to treat and prevent infectious diseases, as well as (in countries where allowed) to promote growth and improve feeding efficiency of food-producing animals in livestock activities. Among the different antibiotic classes, tetracyclines and sulfonamides are two of the most used for veterinary proposals. Due to the fact that these compounds are poorly absorbed in the gut of animals, a significant proportion (up to ~90%) of them are excreted unchanged, thus reaching the environment mainly through the application of manures and slurries as fertilizers in agricultural fields. Once in the soil, antibiotics are subjected to a series of physicochemical and biological processes, which depend both on the antibiotic nature and soil characteristics. Adsorption/desorption to soil particles and degradation are the main processes that will affect the persistence, bioavailability, and environmental fate of these pollutants, thus determining their potential impacts and risks on human and ecological health. -
Multi-Residual Quantitative Analytical Method for Antibiotics in Sea Food by LC/MS/MS
PO-CON1742E Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS ASMS 2017 TP 198 Anant Lohar, Shailendra Rane, Ashutosh Shelar, Shailesh Damale, Rashi Kochhar, Purushottam Sutar, Deepti Bhandarkar, Ajit Datar, Pratap Rasam and Jitendra Kelkar Shimadzu Analytical (India) Pvt. Ltd., 1 A/B, Rushabh Chambers, Makwana Road, Marol, Andheri (E), Mumbai-400059, Maharashtra, India. Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS Introduction Antibiotics are widely used in agriculture as growth LC/MS/MS method has been developed for quantitation of enhancers, disease treatment and control in animal feeding multi-residual antibiotics (Table 1) from sea food sample operations. Concerns for increased antibiotic resistance of using LCMS-8040, a triple quadrupole mass spectrometer microorganisms have prompted research into the from Shimadzu Corporation, Japan. Simultaneous analysis environmental occurrence of these compounds. of multi-residual antibiotics often exhibit peak shape Assessment of the environmental occurrence of antibiotics distortion owing to their different chemical nature. To depends on development of sensitive and selective overcome this, autosampler pre-treatment feature was analytical methods based on new instrumental used [1]. technologies. Table 1. List of antibiotics Sr.No. Name of group Name of compound Number of compounds Flumequine, Oxolinic Acid, Ciprofloxacin, Danofloxacin, Difloxacin.HCl, 1 Fluoroquinolones 8 Enrofloxacin, Sarafloxacin HCl Trihydrate, -
Transdermal Drug Delivery Device Including An
(19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. -
A Case Report of Fatal Dapsone-Induced Agranulocytosis in an Indian Mid-Borderline Leprosy Patient
Lepr Rev <2003) 74, 167±170 CASE REPORT A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient RAMESH M. BHAT & K. RADHAKRISHNAN Department of Dermatology, Venereology & Leprosy, Fr. Muller Medical College, Kankanady, Mangalore, Karnataka 575 002, India Accepted for publication 11 February 2003 Summary Fatal agranulocytosis in an Indian male receiving 100 mg of dapsone daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported. Various case reports concerning dapsone-induced agranulocytosis are reviewed. Introduction For the last 60 years, dapsone has been used successfully as both an antibacterial and anti- in¯ammatory agent in leprosy and a range of dermatological disorders. Various haematolo- gical adverse effects, including methaemoglobinaemia, haemolysis and fatal agranulocytosis, have been reported.1 Other rare adverse effects such as pulmonary eosinophilia without cutaneous allergic manifestations have also been reported.2 We have also reported dapsone- induced eosinophilia without pulmonary and cutaneous allergic manifestations.3 The ®rst case of dapsone-induced agranulocytosis was reported in 1958 in a patient receiving dapsone for dermatitis herpetiformis.4 In 1970, a report was published concerning 16 US soldiers in Vietnam who developed agranulocytosis after receiving 25 mg of dapsone daily for malaria prophylaxis with a 50% fatality rate.5 Agranulocytosis has also been reported as a complication of weekly maloprim, a combination of -
Kinetic and Mechanistic Study of the Reaction Between Methane Sulfonamide (CH3S(O)2NH2) and OH
Atmos. Chem. Phys., 20, 2695–2707, 2020 https://doi.org/10.5194/acp-20-2695-2020 © Author(s) 2020. This work is distributed under the Creative Commons Attribution 4.0 License. Kinetic and mechanistic study of the reaction between methane sulfonamide (CH3S.O/2NH2) and OH Matias Berasategui, Damien Amedro, Achim Edtbauer, Jonathan Williams, Jos Lelieveld, and John N. Crowley Division of Atmospheric Chemistry, Max-Planck-Institut für Chemie, 55128 Mainz, Germany Correspondence: John N. Crowley ([email protected]) Received: 8 November 2019 – Discussion started: 28 November 2019 Revised: 30 January 2020 – Accepted: 3 February 2020 – Published: 4 March 2020 Abstract. Methane sulfonamide (MSAM), CH3S.O/2NH2, The main organosulfur trace gases in the marine boundary was recently detected for the first time in ambient air over the layer are dimethyl sulfide (CH3SCH3, DMS) and its oxi- Red Sea and the Gulf of Aden where peak mixing ratios of dation products dimethyl sulfoxide (DMSO), dimethyl sul- ≈ 60 pptv were recorded. Prior to this study the rate constant fone (DMSO2), methyl sulfonic acid (MSA), and methyl for its reaction with the OH radical and the products thereby sulfinic acid (MSI) for which atmospheric lifetimes with re- formed were unknown, precluding assessment of its role in spect to their degradation by the OH radical vary between the atmosphere. We have studied the OH-initiated photo- hours (DMS) and several weeks (DMSO2). oxidation of MSAM in air (298 K, 700 Torr total pressure) Recently, the first detection of methane sulfonamide in a photochemical reactor using in situ detection of MSAM (CH3S.O/2NH2, MSAM) in ambient air was made during and its products by Fourier transform infrared (FTIR) absorp- the Air Quality and Climate Change in the Arabian Basin tion spectroscopy. -
AMR in Fisheries and Aquaculture Products
AMR in fisheries and aquaculture products Products, Trade and Marketing Branch Fisheries and Aquaculture Department Food and Agriculture Organization of the United Nations What accelerates the emergence and spread of AMR? Poor infection control, inadequate sanitary conditions and misused of antimicrobials among others Role of modifiable drivers for antimicrobial resistance: a conceptual framework (Alison H Holmes, 2015) EU FISH AND CRUSTACEANS PRODUCT ALERTS Hazard Category 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Microbiological 52 75 11 17 24 68 70 65 52 31 58 38 38 Chemical and 118 177 203 221 108 135 123 149 134 170 221 128 133 residues Histamine 39 22 29 44 39 51 35 32 44 53 40 33 42 Toxins 0 0 0 0 0 0 0 0 0 0 0 2 4 Parasitic infestation 51 21 15 27 38 70 85 96 54 11 18 11 22 Others 33 14 29 35 46 120 123 137 127 73 43 83 88 TOTAL ALERTS 293 309 287 344 255 444 436 479 411 338 380 295 327 Hazard Category 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Microbiological 51 25 6 4 8 8 13 7 9 3 6 10 15 Chemical and 103 128 122 108 111 145 43 40 31 24 57 31 46 residues Others 5 1 10 9 3 23 22 29 20 26 14 17 8 Biotoxins 0 2 1 0 0 0 0 0 0 0 0 0 0 TOTAL ALERTS 159 156 139 121 122 176 78 76 60 53 77 58 69 Source: Rapid Alert System for Food and Feed, European Commission IMPORT REFUSALS DUE TO CHEMICAL HAZARDS IN EU DIOXINS 2% 35 ADDITIVES 4% 30 25 BENZO(a)PYRENE 6% 20 OTHER CHEMICAL HAZARDS 8% 15 10 5 ANTIMICROBIALS 18% 0 HEAVY METALS 62% 2010 2011 2012 2013 2014 2015 2016 JAPAN FISHERY PRODUCTS DETENTION -
(MSAM), DMS and DMSO2 Measured in Air Over the Arabian Sea Achim Edtbauer1, Christof Stönner1, Eva Y
A new marine biogenic emission: methane sulfonamide (MSAM), DMS and DMSO2 measured in air over the Arabian Sea Achim Edtbauer1, Christof Stönner1, Eva Y. Pfannerstill1, Matias Berasategui1, David Walter1,2, John N. Crowley1, Jos Lelieveld1,3, and Jonathan Williams1,3 1Atmospheric Chemistry Department, Max Planck Institute for Chemistry, Mainz, Germany 2Department Biogeochemical Processes, Max Planck Institute for Biogeochemistry, Jena, Germany 3Energy, Environment and Water Research Center, The Cyprus Institute, Nicosia, Cyprus Correspondence: Achim Edtbauer ([email protected]) Abstract. We present the first ambient measurements of a new marine emission methane sulfonamide (MSAM: CH5NO2S), along with dimethyl sulfide (DMS) and dimethyl sulfone (DMSO2) over the Arabian Sea. Two shipborne transects (W ! E, E ! W) were made during the AQABA (Air Quality and Climate Change in the Arabian Basin) measurement campaign. Molar mixing ratios in picomole of species per mole of air (throughout this manuscript abbreviated as ppt) of DMS were in the range 5 300–500 ppt during the first traverse of the Arabian Sea (first leg) and 100–300 ppt in the second leg. In the first leg DMSO2 was always below 40 ppt and MSAM was close to the limit of detection. During the second leg DMSO2 was between 40–120 ppt and MSAM was mostly in the range 20–50 ppt with maximum values of 60 ppt. An analysis of HYSPLIT back trajectories combined with calculations of the exposure of these trajectories to underlying chlorophyll in the surface water revealed that most MSAM originates from the Somalia upwelling region, known for its high biological activity. MSAM emissions can be as 10 high as one third of DMS emissions over the upwelling region. -
Sulfonamides and Sulfonamide Combinations*
Sulfonamides and Sulfonamide Combinations* Overview Due to low cost and relative efficacy against many common bacterial infections, sulfonamides and sulfonamide combinations with diaminopyrimidines are some of the most common antibacterial agents utilized in veterinary medicine. The sulfonamides are derived from sulfanilamide. These chemicals are structural analogues of ρ-aminobenzoic acid (PABA). All sulfonamides are characterized by the same chemical nucleus. Functional groups are added to the amino group or substitutions made on the amino group to facilitate varying chemical, physical and pharmacologic properties and antibacterial spectra. Most sulfonamides are too alkaline for routine parenteral use. Therefore the drug is most commonly administered orally except in life threatening systemic infections. However, sulfonamide preparations can be administered orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically. Sulfonamides are effective against Gram-positive and Gram-negative bacteria. Some protozoa, such as coccidians, Toxoplasma species and plasmodia, are generally sensitive. Chlamydia, Nocardia and Actinomyces species are also sensitive. Veterinary diseases commonly treated by sulfonamides are actinobacillosis, coccidioidosis, mastitis, metritis, colibacillosis, pododermatitis, polyarthritis, respiratory infections and toxo- plasmosis. Strains of rickettsiae, Pseudomonas, Klebsiella, Proteus, Clostridium and Leptospira species are often highly resistant. Sulfonamides are bacteriostatic antimicrobials -
On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis
separations Review On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis Victoria Samanidou *, Dimitrios Bitas, Stamatia Charitonos and Ioannis Papadoyannis Laboratory of Analytical Chemistry, University of Thessaloniki, GR 54124 Thessaloniki, Greece; [email protected] (D.B.); [email protected] (S.C.); [email protected] (I.P.) * Correspondence: [email protected]; Tel.: +30-2310-997698; Fax: +30-2310-997719 Academic Editor: Frank L. Dorman Received: 2 February 2016; Accepted: 26 February 2016; Published: 4 March 2016 Abstract: The widespread use of antibiotics in veterinary practice and aquaculture has led to the increase of antimicrobial resistance in food-borne pathogens that may be transferred to humans. Global concern is reflected in the regulations from different agencies that have set maximum permitted residue limits on antibiotics in different food matrices of animal origin. Sensitive and selective methods are required to monitor residue levels in aquaculture species for routine regulatory analysis. Since sample preparation is the most important step, several extraction methods have been developed. In this review, we aim to summarize the trends in extraction of several antibiotics classes from shrimps and give a comparison of performance characteristics in the different approaches. Keywords: sample preparation; extraction; aquaculture; shrimps; chromatography; antibiotics 1. Introduction According to FAO (CWP Handbook of Fishery Statistical Standards, Section J: AQUACULTURE), “aquaculture is the farming of aquatic organisms: fish, mollusks, crustaceans, aquatic plants, crocodiles, alligators, turtles, and amphibians. Farming implies some form of intervention in the rearing process to enhance production, such as regular stocking, feeding, protection from predators, etc.”[1]. Since 1960, aquaculture practice and production has increased as a result of the improved conditions in the aquaculture facilities. -
Sulfonanilide Compounds
~" ' Nil II II II Nil 1 1 Nil II MINI II J European Patent Office o «i -» © Publication number: 0 31/ 332 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 19.05.93 © Int. CI.5: C07C 311/08, C07D 309/12, C07D 211/46, C07C 317/14, © Application number: 88310899.5 C07C 323/18, C07D 335/02, A61K 31/18, A61K 31/33 (5)nn, Date of filing: 18.11.88AOAAOO ' © Sulfonanilide compounds. ® Priority: 19.11.87 JP 292856/87 Urawa-shi(JP) Inventor: Ohuchi, Yutaka @ Date of publication of application: Azumaso 101, 12-11 Oyaba-2-chome 24.05.89 Bulletin 89/21 Urawa-shl(JP) Inventor: Sekluchl, Kazuto © Publication of the grant of the patent: 2716-4-1-204 Oaza Kawarabukl 19.05.93 Bulletin 93/20 Ageo-shl(JP) Inventor: Salto, Shlujl © Designated Contracting States: Pakusaldo Maehara 202 31-12, Torocho- AT BE CH DE FR GB IT LI LU NL SE 1 - chome Omlya-shl(JP) © References cited: Inventor: Hatayama, Katsuo EP-A- 0 093 591 Danchl 35-3 1200-215, Horlsaklcho FR- A- 2 244 473 Omlya- shl(JP) US- A- 3 725 451 Inventor: Sota, Kaoru US-A- 3840 597 1158- 11, Shlmotoml US- A- 3 856 859 Tokorozawa- shl(JP) © Proprietor: TAISHO PHARMACEUTICAL CO. LTD © Representative: Colelro, Raymond et al 00 24- 1 Takata 3- chome Toshlma- ku MEWBURN ELLIS & CO. 2/3 Cursltor Street CM Tokyo 1 71 (JP) London EC4A 1BQ (GB) CO CO @ Inventor: Yoshlkawa, Kensel IV 2878, Dalmon CO Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. -
Sales of Veterinary Antimicrobial Agents in 29 European Countries in 2014
Sales of veterinary antimicrobial agents in 29 European countries in 2014 Trends across 2011 to 2014 Sixth ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role • publishes impartial and comprehensible information about medicines and their use; The European Medicines Agency is the European Union body responsible for coordinating the existing scientific resources • develops best practice for medicines evaluation and put at its disposal by Member States for the evaluation, supervision in Europe, and contributes alongside the supervision and pharmacovigilance of medicinal products. Member States and the European Commission to the harmonisation of regulatory standards at the international The Agency provides the Member States and the institutions level. of the European Union (EU) and the European Economic Area (EEA) countries with the best-possible scientific advice Guiding principles on any questions relating to the evaluation of the quality, safety and efficacy of medicinal products for human or • We are strongly committed to public and animal health. veterinary use referred to it in accordance with the provisions of EU legislation relating to medicinal products. • We make independent recommendations based on scien- tific evidence, using state-of-the-art knowledge and The founding legislation of the Agency is Regulation (EC) expertise in our field. No 726/2004. • We support research and innovation to stimulate the Principal activities development of better medicines. Working with the Member States and the European Commission as partners in a European medicines network, the European • We value the contribution of our partners and stakeholders Medicines Agency: to our work.